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ABSTRACT
Introduction: Palmoplantar psoriasis (PP) and
palmoplantar pustulosis (PPP) are diseases
affecting the hands and/or feet that can cause
marked physical discomfort and functional
disability. The tumor necrosis factor-alpha
antagonists adalimumab, etanercept, and
infliximab, the interleukin (IL)-17A inhibitors
ixekizumab and secukinumab, and the IL-23 or
IL-12/IL-23 inhibitors guselkumab and ustek-
inumab have been well studied for the treat-
ment of moderate to severe plaque psoriasis.
Less is known about the efficacy and safety of
these agents for the treatment of PP (hyperker-
atotic and pustular forms) and PPP. The aim of
this review was to investigate the efficacy of
biologic therapy for the treatment of hyperker-
atotic PP, pustular PP, and PPP.
Methods: A systematic search of the medical
electronic databases (Medline, Embase, and
Cochrane Library) was conducted to identify
studies or case reports which both used biologic
therapy for the treatment of hyperkeratotic PP,
pustular PP, and PPP and reported treatment
outcomes.
Results: The systematic search identified 579
published articles, of which 44 were included in
the analysis. Seven of the articles involved ran-
domized placebo-controlled trials, two were
open label trials, and the remaining were cohort
studies, case series, or case reports. In the ran-
domized controlled trials on the treatment of
hyperkeratotic PP, adalimumab, guselkumab,
infliximab, ixekizumab, and secukinumab each
demonstrated superiority to placebo at 16, 16,
14, 12, and 12 or 16 weeks, respectively
(p\0.05). For the treatment of pustular PP,
ustekinumab 45 mg was not superior to placebo
at 12 and 16 weeks, respectively (p[0.05),
although an open label study demonstrated that
four of five patients on a therapeutic regimen of
ustekinumab 90 mg achieved clinical clearance
at 16 weeks. For the treatment of PPP, etanercept
and ustekinumab 45 mg were not superior to
placebo at 12 and 16 weeks, respectively
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(p[0.05). A combined analysis of studies for
hyperkeratotic PP demonstrated that 94.7%,
90.0%, 82.5%, 89.1%, and 86.7% of patients
experienced an improvement of at least 50%
upon treatment with adalimumab, guselkumab,
ixekizumab, secukinumab, and ustekinumab,
respectively. In a combined analysis of case
reports examining PPP, infliximab showed the
greatest efficacy at 100.0% clinical improvement
of patients from case reports, followed by ustek-
inumab at 58.8% clinical improvement. Few
serious adverse events were reported, but several
were reported in patients treated with infliximab
or secukinumab.
Conclusion: Biologic therapy is effective and
well-tolerated for the treatment of hyperkera-
totic PP, but less data are available on the treat-
ment of pustular PP or PPP. Adalimumab,
guselkumab, ixekizumab, secukinumab, and
ustekinumab all showed[80% efficacy for the
treatment of hyperkeratotic PP, while infliximab
and ustekinumab showed moderate efficacy for
the treatment of pustular PP, and infliximab was
the most efficacious treatment for PPP.
Keywords: Adalimumab; Biologic therapy;
Etanercept; Infliximab; Ixekizumab;
Palmoplantar psoriasis; Palmoplantar
pustulosis; Pustular psoriasis; Secukinumab;
Ustekinumab
INTRODUCTION
Palmoplantar psoriasis (PP) is a chronic, debili-
tating disease of the palms and/or soles that
affects 11–39% of psoriasis patients [1–3]. The
morphology of PP can range from thick,
hyperkeratotic plaques with fissuring to pustu-
lar lesions of the palms and/or soles, and PP is
often classified into subtypes based on this
morphologic distinction [4, 5]. Hyperkeratotic
PP refers to sharply defined erythematous scaly
plaques with overlying hyperkeratosis and
without the presence of sterile pustules, pre-
dominantly at the palms and/or soles [6]. Pus-
tular PP is a variant that includes macroscopic
sterile pustules and erythema with intermixed
yellow–brown macules localized to the palms
and/or soles [6]. PP causes greater physical
discomfort and functional disability than pso-
riasis limited to other body areas, and it is often
recalcitrant to treatment [2].
Palmoplantar pustulosis (PPP) is a bilateral,
symmetric dermatosis that also affects the
hands and/or feet and is clinically distin-
guished from PP based on the absence of
psoriasis at other body sites and a predilection
for histologic involvement of the acrosy-
ringium (the terminal duct of eccrine sweat
glands) [6, 7]. Pustular PP and hyperkeratotic
PP mostly occur concomitantly with psoriasis
at other body areas, while PPP consists of
pustular lesions typically limited to the palms
and/or soles that appear on a clear, non-ery-
thematous background [6–8]. However, whe-
ther PPP can be considered a clinical spectrum
of plaque psoriasis or whether it is an inde-
pendent disease is open to much debate.
Consequently, in the literature, pustular PP
and PPP are often not well distinguished.
Some studies have identified the involvement
of the acrosyringium as being more specific to
PPP [7, 9]. Demographically, PPP is character-
ized by a female predominance and strong
association with smoking, whereas no such
associations exist for pustular PP [6, 7]. Inter-
estingly, in individuals with PPP, nicotine is
thought to be secreted into eccrine glands to
promote inflammation and alter the local
response to infection [7]. Recent genetic
studies have challenged the relationship of
PPP with plaque psoriasis, although both
these conditions can respond to similar treat-
ments and have a similar impact on quality of
life.
Topical therapy and phototherapy are first--
line modalities for the management of PP and
PPP. However, the majority of patients eventu-
ally require treatment with systemic medica-
tions [3]. Traditionally, agents such as oral
retinoids, methotrexate, and cyclosporin have
been utilized, but these medications carry risks
of adverse effects that may limit their use in
clinical practice.
Biologic agents have been well studied for
the treatment of moderate to severe chronic
plaque psoriasis, but less is known about the
efficacy of these medications for the treatment
of PP and PPP. We have therefore performed a
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systematic review of the use of biologic agents
for the treatment of hyperkeratotic PP, pustular
PP, and PPP with the aim to provide clinicians
with helpful information when considering
management options for these disabling
conditions.
METHODS
The biomedical and healthcare journal data-
bases of Ovid National Library of Medicine’s
Medical Literature Analysis and Retrieval Sys-
tem (MEDLINE), Embase, and the Cochrane
Library were searched to identify published
articles that assessed the efficacy and safety of
biologic agents for the treatment of hyperkera-
totic PP, pustular PP, and PPP. The detailed
search strategy is presented in Electronic Sup-
plementary Material Fig. 2. Abstracts were
screened, and articles that appeared to meet the
inclusion criteria were assessed further. Refer-
ence lists of relevant articles were scrutinized to
identify additional reports.
Eligibility Criteria
Publications were included if subjects were
diagnosed with PP or PPP based on the assess-
ment by the authors of each publication and if
subjects received treatment with one of the
currently approved biologics for psoriasis,
namely, adalimumab, brodalumab, etanercept,
guselkumab, infliximab, ixekizumab, secuk-
inumab, or ustekinumab. Publications were
required to report the efficacy and/or safety
outcomes of the biologic treatment. Publica-
tions describing the treatment of cases of PPP
induced by exposure to biologic medications
were excluded due to the likely distinct patho-
physiology of drug-induced PPP.
Study Selection and Data Extraction
Three reviewers (E.S., I.S., E.L.) independently
conducted publication selection (Fig. 1). Any
discrepancies were resolved by an additional
reviewer (W.L.). Studies were categorized based
on the morphology of palmoplantar lesions.
Study characteristics (author, year of publica-
tion, design, number of patients, intervention,
duration of treatment, outcome, and key safety
indicators) and subject characteristics (age, sex,
comorbidities, morphological variant, severity
at baseline, involvement of sites other than the
palms and soles, and prior treatments) were
extracted using a standardized data abstraction
form designed for this review. Efficacy out-
comes were recorded in Table 1, defined as a
50% reduction in the PPP Area and Severity
Index (PPASI-50) if available, otherwise a 75%
reduction in PPASI (PPASI-75) or an Investiga-
tor Global Assessment (IGA) score of 0/1
(cleared/minimal disease) was used. If two
biologics were studied in one study, both were
described in Tables 1, 2, 3 and 4 under the
category of the primary biologic that was
studied, but the efficacy data of both biologics
were used to calculate the summary of clinical
improvement outcomes in Table 5. Due to the
heterogeneity of outcome measures, outcomes
were reported as described by the authors of
each publication.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
The initial search yielded 731 articles. After
excluding duplicates, we screened 579 reports
by title and abstract, of which identified 76
articles for full-text review. Following the full--
text review, we ultimately included 44 publica-
tions reporting the use of a biologic medication
in the treatment of PP and PPP in the analysis,
seven and two of which were randomized con-
trolled trials (RCTs) and open-label trials,
respectively (Table 1) [10–22]. The remaining
publications were case reports or case series
[20–53].
A total of 722 cases of hyperkeratotic PP, 63
cases of pustular PP, and 58 cases of PPP were
included in the analysis. Almost all patients in
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the included studies were adults. The specifics
of age, gender, comorbidities, and previous
therapies are shown in Tables 1, 2, 3 and 4. The
previous use of systemic therapy was not con-
sistently reported in all patients. Many patients
received prior systemic therapy and some had
received prior biologic therapy. Several subjects
had responded to phototherapy, and nearly all
had not responded to topical therapy.
Efficacy
The results of each publication are summarized
in Tables 1, 2, 3 and 4. The characteristics
describing each study are reported in Tables S1,
S2, S3, and S4. The proportion of patients
demonstrating clinical improvement is reported
in Table 5.
Hyperkeratotic PP
In the RCT performed by Leonardi et al. [14], a
greater number of patients with hyperkeratotic
PP treated with adalimumab achieved a clinical
score of clear or almost clear at 16 weeks com-
pared to patients treated with placebo (30.6%
vs. 4.3%; p = 0.01). Response was maintained at
28 weeks by 80% of these subjects. Of the
patients in the RCT or case reports who were
treated with adalimumab, 94.7% demonstrated
an overall clinical improvement. In another
RCT by Bissonnette et al. [13], a greater pro-
portion of patients with hyperkeratotic PP
treated with infliximab achieved at least a 50%
reduction in clinical severity at 14 weeks com-
pared to patients treated with placebo (66.7%
vs. 8.3%; p = 0.01). These authors also reported
that infliximab was superior to placebo in the
reduction of mean area of involvement (50
decrease vs. 15% increase; p = 0.01). Overall,
75% of all patients studied using infliximab
demonstrated clinical improvement. In their
clinical trial, Blauvelt et al. [15] observed a sig-
nificant clinical clearance among those patients
treated with guselkumab when compared to
those receiving placebo at 16 weeks (85.1%
reaching an IGA score of 0 or 1; p\0.001).
Clinical improvement was observed in 90% of
all patients studied receiving treatment with
Fig. 1 Process of study selection
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guselkumab. In three phase 3 trials conducted
by Menter et al. [17], a greater proportion of the
patients treated with ixekizumab showed clini-
cal improvement compared to those treated
with etanercept or those receiving placebo
(PPASI-50: 80 vs. 67.8 vs. 32.9, respectively;
p\0.05). Overall, 82.5% of the patients studied
who were using ixekizumab demonstrated
clinical improvement. Significant clinical
clearance was achieved in a RCT that compared
secukinumab at a dose of 300 or 150 mg to
placebo [palmoplantar psoriasis IGA (PPIGA)
score of 0 or 1: 33.3% (300 mg dose), 22.1% (150
mg dose), vs. 1.5%; p\0.001 and p = 0.002,
respectively] [16]. The proportion of patients in
all studies demonstrating clinical improvement
after completing treatment with secukinumab
was 89.1%. In an uncontrolled open label study
of ustekinumab, 20% patients with hyperkera-
totic PP achieved clinical clearance after
16 weeks of therapy [10]. Clinical clearance was
achieved by 50% of patients receiving a 90 mg
dosage regimen, while no patients receiving a
45 mg regimen achieved clearance.
A number of case series and case reports
describe effective treatment of hyperkeratotic
PP with etanercept, alefacept, infliximab, and
ustekinumab (Tables 1, 4) [21, 25, 26, 33, 34,
41–43, 52].
Pustular PP
In a small RCT by Bissonnette et al. [11],
ustekinumab 45 mg was not superior to placebo
in achieving at least a 50% reduction in clinical
severity among patients with pustular PP after
16 weeks of therapy (p = 1.00). In an open label
study by Au et al. [10], half of the patients with
pustular PP treated with ustekinumab achieved
clinical clearance after 16 weeks of therapy. A
greater proportion of patients receiving a 90 mg
regimen of ustekinumab achieved clearance
compared to those receiving a 45 mg regimen
(80% vs. 20%). In another open label study,
54.5% of patients with pustular or hyperkera-
totic PP who were treated with adalimumab
reached clinical clearance after 12 weeks of
therapy [19].
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In addition, case series and case reports
describe effective treatment of pustular PP with
adalimumab, etanercept, infliximab, and
ustekinumab
[24, 26, 28, 30, 34, 35, 37, 39, 45, 51, 52, 54]. In
contrast, other case reports show ineffective
treatment with adalimumab or mixed responses
to ustekinumab (Tables 2, 4) [27, 54].
Palmoplantar Pustulosis
In a RCT of patients with PPP conducted by
Bissonnette et al. [12], treatment with etaner-
cept was not found to be superior to placebo at
the primary endpoint of 12 weeks of therapy
(p = 0.426). Interestingly, smoking may have
played a role in treatment efficacy, as the
authors noted that three of three nonsmokers
achieved clinical improvement with etanercept
therapy while only three of seven active smok-
ers demonstrated improvement. In a small RCT
by Bissonnette et al. [11], ustekinumab 45 mg
was not found to be superior to placebo at
16 weeks of therapy (p = 1.00).
Case reports and case series describe effective
treatment of PPP with etanercept, infliximab,
and ustekinumab [20, 29, 31, 32, 46–50, 53, 54].
Multiple reports of treatment with infliximab
describe a period of initial improvement with
eventual recurrence (Tables 3, 4) [36, 38, 40].
Safety
Serious adverse events (SAEs) were infrequently
reported. The majority of cases occurred in
patients treated with infliximab, and the SAEs
included cellulitis, hepatitis, an urticarial infu-
sion reaction, a serum sickness-like infusion
reaction, and autoimmune hepatitis
[13, 34, 36, 38]. One subject with a history of a
positive tuberculin skin test developed reacti-
vation tuberculosis while undergoing treatment
with etanercept for pustular PP [30]. In the
GESTURE RCT that used secukinumab as treat-
ment for hyperkeratotic PP, 5.9% of patients
developed SAEs while on a 150 mg therapeutic
regimen and 2.9% of patients developed SAEs
while on a 300 mg therapeutic regimen, com-
pared to 2.9% that developed SAEs while usingT
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Table 5 Clinical improvement of palmoplantar psoriasis or palmoplantar pustulosis following treatment with biologic
agent
Medication Variant treated Total
number of
cases
Cases in which patients
demonstrated
improvementa
Serious adverse events
Adalimumab Hyperkeratotic PP [14, 15] 150 142 (94.7%) No SAEs reported
Pustular PP [24] 1 1 (100.0%) No SAEs reported
PPP [22, 23, 50, 53] 7 2 (28.6%) No SAEs reported
Totalb 169 152 (89.9%)
Alefacept Hyperkeratotic PP [21] 2 2 (100.0%) No SAEs reported
Pustular PP 0 0
PPP 0 0
Total 2 2 (100.0%)
Anakinra Hyperkeratotic PP [52] 1 1 (100.0%) No SAEs reported
Pustular PP [52] 1 1 (100.0%) No SAEs reported
PPP 0 0
Total 2 2 (100.0%)
Etanercept Hyperkeratotic PP [17, 25] 60 41 (68.3%) No SAEs reported
Pustular PP [27, 28, 30] 3 2 (66.7%) Reactivation of latent TB
PPP [12, 22, 29, 31, 32, 49] 23 13 (56.5%) No SAEs reported
Totalb 87 57 (65.5%)
Guselkumab Hyperkeratotic PP [15] 100 90 (90.0%) No SAEs reported
Pustular PP 0 0
PPP 0 0
Total 100 90 (90.0%)
Infliximab Hyperkeratotic PP
[13, 33, 34]
32 24 (75.0%) Cellulitis, hepatitis,
infusion-related urticarial
reaction
Pustular PP [35, 37, 39] 8 4 (50.0%)
PPP
[20, 22, 34, 36, 38, 40, 50]
8 8 (100.0%) Serum sickness-like infusion
reaction, autoimmune
hepatitis
Totalb 49 37 (75.5%)
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placebo. However, the authors of this study did
not report the statistical significance of the
SAEs. None of these SAEs were cardiac-related,
and there were no opportunistic infections or
fatalities [16].
Special Populations
Three patients with chronic hepatitis C virus
(HCV) were treated with biologic medications
for PP without hepatologic complications
[30, 34, 45]. One patient with chronic HCV
displayed an infusion-related urticarial reaction
during infliximab treatment, leading to dis-
continuation of the medication [34]. One
patient with comorbid untreated latent
tuberculosis developed reactivation tuberculosis
after 4 years of therapy with etancercept [34].
One pediatric patient was treated with etaner-
cept with no reported SAEs [28].
DISCUSSION
The advent of biologic medications has greatly
enhanced the treatment of moderate to severe
plaque psoriasis. Current evidence suggests that
biologic agents may also be effective therapeutic
options for the treatment of hyperkeratotic PP,
with less evidence supporting their use in pus-
tular PP and PPP.
For hyperkeratotic PP, results from RCTs
(level 1 evidence) suggest that adalimumab,
Table 5 continued
Medication Variant treated Total
number of
cases
Cases in which patients
demonstrated
improvementa
Serious adverse events
Ixekizumab Hyperkeratotic PP [17] 206 170 (82.5%) No SAEs reported
Pustular PP 0 0
PPP 0 0
Total 206 170 (82.5%)
Secukinumab Hyperkeratotic PP [16, 18] 183 63 (89.1%) 150 mg 5.9% SAE, 300 mg
2.9% SAE, placebo 2.9%
SAEc
Pustular PP 0 0
PPP 0 0
Total 183 63 (89.1%)
Ustekinumab Hyperkeratotic PP
[10, 41–43]
15 13 (86.7%) No SAEs reported
Pustular PP
[10, 11, 45, 51, 54]
40 22 (55.0%) No SAEs reported
PPP [11, 46–48, 53, 54] 17 10 (58.8%) No SAEs reported
Total 72 45 (62.5%)
SAE serious adverse event
a Using most conservative estimate [PPASI-50 if available; otherwise, if reported, a PPASI-75 or an IGA score of 0/1
(cleared/minimal disease)]
b Includes data from Richetta et al. [19], and Spuls et al. [26] in which specific morphology is not described
c No SAEs were fatal, no cardiac events, and no opportunistic infections
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guselkumab, ixekizumab, infliximab, and
secukinumab are effective treatment options.
While ustekinumab has not been evaluated in a
RCT of patients with hyperkeratotic PP, in an
open label study (level 3 evidence), one-half of
patients receiving a 90 mg regimen achieved
clinical clearance.
For pustular PP, ustekinumab 45 mg did not
appear to be more effective than placebo (level 1
evidence) in patients participating in a small
RCT. However, the majority of patients (80%)
with pustular PP receiving a 90 mg regimen of
ustekinumab in an open label study did achieve
clinical clearance [10]. With the exception of
ustekinumab, limited information on pustular
PP treatment can be found in the literature. We
found only eight pustular PP patients treated
with infliximab, three patients with etanercept,
and one patient each treated with adalimumab
and anakinra. We found no reports of pustular
PP treatment with alefacept, guselkumab, ixek-
izumab, or secukinumab. Of note, in all of the
pustular PP case reports, patients were treated
with the standard dose of biologic for plaque
psoriasis. The lack of response in many of these
cases suggests the possibility that pustular PP
may require higher doses of biologics than
hyperkeratotic PP or body plaque psoriasis in
order to achieve efficacy.
For the treatment of PPP, the results of two
small RCTs suggest that treatment with etaner-
cept and ustekinumab 45 mg may not be more
effective than placebo (level 1 evidence). How-
ever, the study of ustekinumab included only
five patients in the active treatment arm, and
no patient received a 90 mg regimen of this
biologic [11, 54]. Overall, infliximab appeared
to have the greatest efficacy for PPP compared
to other biologics, followed by ustekinumab. It
is important to note that the quality of these
conclusions is limited since most of the data
were from case reports or case series.
Although case series and case reports offer
less rigorous evidence for the efficacy of biologic
agents in PP and PPP, they do illustrate a few
notable trends. For example, ustekinumab has
been shown to be effective in multiple cases of
PP and PPP refractory to tumor necrosis fac-
tor-alpha (TNF-a) inhibitor therapy
[10, 43, 45, 47, 48]. Additionally, infliximab
appears to have a higher risk of SAEs compared
to other biologics, and it may also demonstrate
loss of efficacy over the course of treatment
[13, 34, 36–38, 40]. In one RCT, patients treated
with secukinumab 150 mg showed a greater
percentage of SAEs than those receiving placebo
(5.9% vs 2.9%, respectively), but there was no
dose effect, with the secukinumab 300 mg
group having a SAE rate of 2.9%, which was
identical to that of the group receiving placebo
[16]. These data indicate that secukinumab may
not be truly associated with SAEs, since there is
not an observable dose–response relationship or
trend.
Importantly, while there have been reports
of new-onset PPP or exacerbation of existing
PPP during TNF-a inhibitor therapy [55–58],
only one clearly reported case of exacerbation of
PPP, in response to infliximab, was identified in
our review of patients with baseline PP and PPP
[37]. In one RCT, four patients (40.0%) with PPP
treated with etanercept experienced increases in
disease severity over the first 12 weeks of treat-
ment, but it is not clear whether these were
drug-induced exacerbations or simply reflective
of a nonresponse to treatment and disease pro-
gression [12].
Notably, two recent studies based on sub-
analysis of Phase II data for secukinumab
demonstrated high rates of response among
patients with hyperkeratotic PP, with up to 71%
of patients achieving clinically significant
improvement [59, 60]. Further studies of novel
biologic agents developed for the treatment of
moderate to severe plaque psoriasis may yield
new therapeutic options for PP and PPP.
The difference in response to biologics
observed between PP and PPP may be explained
by some notable differences in their genetic
profiles. The psoriasis susceptibility gene locus
(PSORS1) that is strongly linked to psoriasis is
not found in patients with PPP. Additionally,
both a missense mutation in the interleukin
(IL)-36 receptor antagonist (IL36RN) and cas-
pase recruitment domain family member 14
(CARD14) have been identified in patients with
PPP, which could influence patient response to
treatment with biologics [9, 61]. However, both
PP and PPP involve IL-17 as a mediator of
inflammation, in addition to interferon-gamma
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and TNF-a. The shared histologic features of the
diseases, consisting of spongiform pustules and
inflammatory infiltrates, may account for some
of the overlap in treatment response and clini-
cal appearance [7, 9]. There is a need for future
studies to explore these genetic differences
further.
Several limitations to our analysis make it
difficult to assess the efficacy of biologic med-
ications in PP and PPP. First, patients with PP
and PPP are often excluded from clinical trials
due to recruitment requirements that patients
be diagnosed with stable plaque psoriasis with
no pustular component and demonstrate
involvement of at least 10% of the body sur-
face area. Second, some of the RCTs using
biologics for these skin diseases, especially for
pustular PP, although completed, are not pub-
lished yet and therefore could not be included
in our review. Third, reporting bias in case
reports and case series makes it difficult to
determine the true rates of response to biologic
agents. Fourth, differences in the use of metrics
to quantify the severity of PP and PPP impose
challenges when comparing rates of response
across studies. In addition, only one small RCT
was available for pustular PP and another for
PPP, with the majority of RCTs specific to
hyperkeratotic PP.
Currently, a number of different scales are
used to assess the severity of PP and PPP, and in
many case reports and case series no metrics are
used at all. Future studies should attempt to
standardize the heterogeneity of clinical metrics
to allow for a more rigorous comparison of the
efficacy of biologic medications in PP and PPP.
In some RCTs, only mean changes in clinical
scores are reported without information on
patient-specific responses. In the most basic
schema, the number of patients who achieve
clearance and the number who demonstrate
objective improvement should be reported.
Further, studies should consistently report the
presence or absence of psoriasis at other body
areas and stratify results based on this
information.
Nonetheless, patient reported outcomes and
functional metrics, such as the survey devel-
oped by Farley et al., may be more important
than visual metrics in evaluating response to
treatment in PP and PPP [5]. Complete clear-
ance may not be necessary if patients achieve
sufficient improvement to perform activities of
daily living and occupational tasks without pain
or discomfort [2].
CONCLUSION
Overall, biologics are effective and well-toler-
ated for the treatment of hyperkeratotic PP, as
demonstrated by the[ 80% efficacy for adali-
mumab, guselkumab, ixekizumab, secuk-
inumab, and ustekinumab. The strong support
for effective hyperkeratotic PP treatment is
derived from multiple large RCTs, and thus
providers may consider tailoring their treat-
ment to include biologics earlier when a patient
presents with this recalcitrant chronic disease.
Infliximab and ustekinumab showed moderate
efficacy for pustular PP, but the data were lim-
ited to small trials or case reports. Less data are
available for the treatment of PPP; however, to
date infliximab is the most efficacious treat-
ment. Future studies are needed to further assess
the efficacy of biologic medications in the
treatment of PP and PPP. In addition, future
research should be performed to compare the
efficacy and safety of biologics with traditional
systemic therapy and phototherapy for these
debilitating and therapeutically challenging
conditions.
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